Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEntropy Neurodynamics Limited

Entropy Neurodynamics Limited

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.029 AUD 0.00(0%)
Last update at 2026-11-12T03:17:00Z
VOLUME
2983947
Market Cap
47.39M

Momentum Score

…

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. In addition, it is pursuing Phase 2 clinical trials using its psilocybin and psilocin-based drug products for chronic pain and eating disorders. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Hawthorn East, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.03
Low
0.03
High
52 Week Price Range
0.03
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Entropy Neurodynamics Limited (ASX:ENP) has limited public disclosure; it appears to be an Australian company focused on neurotechnology research and development. Long-term growth drivers could include expanding clinical applications for neuromodulation, demographic trends increasing neurological disease prevalence, and technological advances that may support commercialisation, which may attract investors seeking early-stage exposure to neuroscience innovation.

Principal investment risks include clinical and regulatory uncertainty typical of neurotechnology ventures, execution and intellectual property challenges, and dependence on external financing that may dilute shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.03
Dividend Yield
-
Revenue TTM
1.91M
Revenue Per Share
0.00
Gross Profit TTM
-1.35M
Debt / Equity
0.37
ROE
-73.07%
Net Debt
-5.58M
ROCE
-91.90%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -6.78M -6.91M -7.25M -7.13M -10.08M
Net income -4.87M -5.33M -6.14M -7.13M -10.08M
Selling general administrative - 4.28M 3.00M 6.41M 9.39M
Selling and marketing expenses - - - 0.09M 0.29M
Gross profit -0.03M -0.05M -0.01M 0.62M 0.10M
Ebit -6.77M -5.32M -6.71M -6.80M -10.00M
Ebitda -6.74M -5.27M -6.70M -5.10M -8.27M
Depreciation and amortization 0.03M 0.05M 0.01M 1.70M 1.73M
Operating income -6.77M -6.73M -4.97M -9.59M -14.11M
Other operating expenses 6.77M 6.73M 4.97M 10.21M 14.21M
Interest expense - 0.01M 0.54M 0.33M 0.08M
Tax provision - 0.00M 0.00M 0.00M -
Interest income - -0.05M -0.54M - -
Income tax expense -1.91M -1.58M -1.11M - -4.06M
Total revenue - 1.59M 1.12M 0.62M 0.10M
Total operating expenses 6.74M 6.68M 4.96M 10.21M 14.21M
Cost of revenue 0.03M 0.05M 0.01M - -
Total other income expense net -0.01M -0.18M -2.28M 2.46M 4.03M
Net income applicable to common shares - -5.33M -6.14M -7.13M -
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 8.38M 6.66M 7.45M 5.88M 13.61M
Intangible assets 0.18M 0.20M 0.37M 0.28M 0.33M
Other current assets 0.44M 0.56M 0.31M 2.88M 4.48M
Total liab 1.02M 0.70M 1.83M 1.75M 4.81M
Total stockholder equity 7.36M 5.96M 5.62M 4.13M 8.81M
Other current liab 0.80M 0.48M 0.56M 0.14M 0.81M
Common stock 41.11M 35.31M 29.91M 36.73M 34.31M
Retained earnings -40.27M -35.41M -30.07M -33.42M -26.29M
Other assets - 0.00M 0.00M 0.00M -
Cash 5.58M 3.03M 5.37M 1.64M 4.85M
Cash and equivalents - 3.03M 5.37M - -
Total current liabilities 1.02M 0.70M 1.83M 1.71M 4.46M
Net debt -5.58M -3.03M -5.37M -0.11M -1.10M
Short term debt - 0.00M 0.00M 1.53M 3.44M
Short long term debt total - - - 1.53M 3.74M
Property plant equipment - 0.11M - 1.01M -
Total current assets 8.11M 6.35M 7.08M 4.59M 9.46M
Net receivables 2.09M 2.76M 1.40M 0.07M 0.13M
Long term debt - - 0.00M - -
Accounts payable 0.22M 0.22M 1.27M 0.04M 0.21M
Accumulated other comprehensive income 6.53M 6.06M 5.78M 0.82M 0.78M
Non currrent assets other 0.00M - 0.00M - 0.58M
Non current assets total 0.28M 0.31M 0.37M 1.30M 4.15M
Long term debt total - 0.00M 0.00M 0.00M -
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total cashflows from investing activities -0.01M -0.13M 1.68M -0.01M -1.24M
Total cash from financing activities 5.97M 5.60M 9.27M 2.39M 1.95M
Net income -4.87M -5.33M -6.14M -5.85M -10.08M
Change in cash 2.55M -2.34M 4.93M -3.20M -7.88M
Begin period cash flow 3.03M 5.33M 0.44M 4.85M 12.72M
End period cash flow 5.58M 3.03M 5.37M 1.64M 4.85M
Total cash from operating activities -3.41M -7.77M -6.00M -4.03M -8.59M
Depreciation 0.03M 0.05M 0.01M - 1.73M
Other cashflows from investing activities - -0.00M 1.68M 0.28M -0.11M
Sale purchase of stock - -0.40M 6.50M - -
Other cashflows from financing activities - -0.40M -0.62M 1.15M -0.78M
Capital expenditures 0.01M 0.13M 0.00M 0.00M 1.13M
Change in working capital 1.12M -2.70M -2.40M 1.20M 6.60M
Other non cash items 0.32M 0.21M 2.53M 0.63M -6.84M
Free cash flow -3.41M -7.90M -6.00M -4.03M -9.72M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ENP
Entropy Neurodynamics Limited		 -
-%		 0.03 - - 24.86 6.21 18.22 -0.27
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Entropy Neurodynamics Limited

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. In addition, it is pursuing Phase 2 clinical trials using its psilocybin and psilocin-based drug products for chronic pain and eating disorders. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Hawthorn East, Australia.

Bio101 Financial Advisory Pty Ltd, Hawthorn East, VIC, Australia, 3123

61 3 9092 0475

https://entropyneurodynamics.com

Name Title Year Born
Mr. Jason Alan Carroll MD, CEO & Executive Director NA
Dr. James P. Gilligan MSIB, Ph.D. President & Chief Scientific Officer 1952
Mr. Christopher Leo Ntoumenopoulos Executive Director 1983
Mr. Hamish George B.Com., C.A. CFO & Company Secretary NA
Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D. Chief Medical Officer 1948
Mr. Christopher Leo Ntoumenopoulos Executive Director 1984
Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D. Chief Medical Officer 1949
Ms. Meghna Piplani Joint Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…